https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:30:00.000Z Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/IMA/imagenebio-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261002 BiopharmaWatch en 2026-10-02T20:30:00.000Z ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:30:00.000Z ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MLYS/lorundrostat-data-asn-kidney-week-2026 BiopharmaWatch en 2026-10-02T20:30:00.000Z Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 https://www.biopharmawatch.com/news/VTAK/catheter-precision-changes-name-ticker-symbol-flyte-aviation BiopharmaWatch en 2026-10-02T20:30:00.000Z Catheter Precision to Change its Name and Ticker Symbol to Flyte Aviation and “VJET” and Effect 1-for-10 Reverse Stock Split, Monday, October 5, at Market Open https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:30:00.000Z Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-10-02T20:05:00.000Z Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-announces-inducement-grant-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-10-02T20:05:00.000Z Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PETS/petmeds-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-10-02T20:05:00.000Z PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-announces-grants-inducement-awards-20261002 BiopharmaWatch en 2026-10-02T20:05:00.000Z Spyre Therapeutics Announces Grants of Inducement Awards https://www.biopharmawatch.com/news/VERA/vera-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:05:00.000Z Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/APMD/apnimed-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-10-02T20:05:00.000Z Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/GLUE/monte-rosa-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:01:00.000Z Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CARL/carlsmed-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-10-02T20:01:00.000Z Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:01:00.000Z Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:01:00.000Z Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inducement-grants-nasdaq-rule BiopharmaWatch en 2026-10-02T20:01:00.000Z Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:01:00.000Z NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-inducement-grants-nasdaq-rule BiopharmaWatch en 2026-10-02T20:01:00.000Z Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-inducement-grants-october-2026 BiopharmaWatch en 2026-10-02T20:01:00.000Z Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T20:00:00.000Z Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/LLY/lilly-jaypirca-fda-approval-untreated-cll-sll BiopharmaWatch en 2026-10-02T19:05:00.000Z Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL https://www.biopharmawatch.com/news/BLCO/dryeye-rescue-exclusive-distributor-scoutpro-bausch-lomb BiopharmaWatch en 2026-10-02T18:47:00.000Z DryEye Rescue Becomes Exclusive U.S. Distributor of ScoutPro by Bausch + Lomb https://www.biopharmawatch.com/news/GMAB/genmab-major-shareholder-announcement BiopharmaWatch en 2026-10-02T17:50:23.000Z Major Shareholder Announcement https://www.biopharmawatch.com/news/SNY/sanofi-karl-anthony-towns-covid-19-vaccination-awareness BiopharmaWatch en 2026-10-02T15:57:00.000Z Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID® https://www.biopharmawatch.com/news/BIIB/biogen-litifilimab-phase-2-results-cutaneous-lupus BiopharmaWatch en 2026-10-02T15:20:00.000Z Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus https://www.biopharmawatch.com/news/PFE/pfizer-litfulo-improves-repigmentation-vitiligo BiopharmaWatch en 2026-10-02T15:15:00.000Z Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo https://www.biopharmawatch.com/news/BMRN/biomarin-five-year-phase-3-data-pombiliti-opfolda BiopharmaWatch en 2026-10-02T15:06:10.769Z BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-zugocabtagene-geleucel-acr-2026 BiopharmaWatch en 2026-10-02T14:15:00.000Z CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 https://www.biopharmawatch.com/news/TVTX/travere-present-new-data-filspari-as-foundational-treatment BiopharmaWatch en 2026-10-02T14:00:00.000Z Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/ICU/seastar-medical-late-breaking-presentation-asn-kidney-week-2026 BiopharmaWatch en 2026-10-02T13:43:00.000Z SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/CLYM/climb-bio-presents-new-data-asn-kidney-week-2026 BiopharmaWatch en 2026-10-02T13:30:00.000Z Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug https://www.biopharmawatch.com/news/VERA/vera-therapeutics-origins-3-asn-kidney-week-2026 BiopharmaWatch en 2026-10-02T13:24:00.000Z Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-presentation-eadv-2026 BiopharmaWatch en 2026-10-02T13:06:00.000Z Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting https://www.biopharmawatch.com/news/OBX/obsidian-therapeutics-amsoki-cel-phase-1-2-data-sitc-2026 BiopharmaWatch en 2026-10-02T13:05:00.000Z Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-acr-convergence-2026-presentations BiopharmaWatch en 2026-10-02T13:05:00.000Z Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 https://www.biopharmawatch.com/news/AGEN/agenus-bot-bal-survival-data-sitc-2026 BiopharmaWatch en 2026-10-02T13:00:00.000Z Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 https://www.biopharmawatch.com/news/EHTH/ehealth-great-place-to-work-certification-2026-27 BiopharmaWatch en 2026-10-02T13:00:00.000Z eHealth Earns 2026-27 Great Place to Work Certification™, Marking Three Consecutive Years of Recognition for Employee Experience https://www.biopharmawatch.com/news/CUPR/cuprina-acquires-singapore-healthcare-group BiopharmaWatch en 2026-10-02T13:00:00.000Z Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group https://www.biopharmawatch.com/news/ITOC/itonic-holdings-share-consolidation-october-2026 BiopharmaWatch en 2026-10-02T13:00:00.000Z iTonic Holdings Ltd Announces 16-for-1 Share Consolidation Effective October 6, 2026 https://www.biopharmawatch.com/news/INKT/mink-therapeutics-sitc-2026-data-presentation BiopharmaWatch en 2026-10-02T13:00:00.000Z MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 https://www.biopharmawatch.com/news/IMRX/immuneering-sitc-2026-presentation-atebimetinib BiopharmaWatch en 2026-10-02T13:00:00.000Z Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) https://www.biopharmawatch.com/news/CADL/candel-therapeutics-sitc-2026-presentation BiopharmaWatch en 2026-10-02T13:00:00.000Z Candel Therapeutics to Present at the SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/PROK/prokidney-abstracts-kidney-week-2026 BiopharmaWatch en 2026-10-02T13:00:00.000Z ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026 https://www.biopharmawatch.com/news/EVAX/evaxion-immune-data-sitc-2026 BiopharmaWatch en 2026-10-02T13:00:00.000Z Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/AIDX/2020-biolabs-maxim-growth-summit-2026 BiopharmaWatch en 2026-10-02T12:31:00.000Z 20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026 https://www.biopharmawatch.com/news/WGS/genedx-easy-order-aap-2026-genomic-testing BiopharmaWatch en 2026-10-02T12:30:00.000Z GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care https://www.biopharmawatch.com/news/RIGL/rigel-pharmaceuticals-inducement-grants-nasdaq BiopharmaWatch en 2026-10-02T12:05:00.000Z Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/IART/integra-lifesciences-q3-results-2026-guidance-update BiopharmaWatch en 2026-10-02T12:05:00.000Z Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance https://www.biopharmawatch.com/news/AMIX/autonomix-medical-patent-technology-advancements BiopharmaWatch en 2026-10-02T12:05:00.000Z Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation https://www.biopharmawatch.com/news/SCNX/scienture-arbli-formularies-pediatric-centers BiopharmaWatch en 2026-10-02T12:05:00.000Z SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals https://www.biopharmawatch.com/news/IPSC/century-therapeutics-cnty-813-easd-2026 BiopharmaWatch en 2026-10-02T12:05:00.000Z Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 https://www.biopharmawatch.com/news/TEVA/dopamine-role-tourette-ecopipam-review BiopharmaWatch en 2026-10-02T12:00:00.000Z Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients https://www.biopharmawatch.com/news/TEVA/teva-ecopipam-tourette-syndrome-data BiopharmaWatch en 2026-10-02T12:00:00.000Z Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome https://www.biopharmawatch.com/news/RVTY/revvity-earnings-call-november-2026 BiopharmaWatch en 2026-10-02T12:00:00.000Z Revvity to Hold Earnings Call on November 3, 2026 https://www.biopharmawatch.com/news/THC/tenet-report-third-quarter-2026-results BiopharmaWatch en 2026-10-02T12:00:00.000Z Tenet to Report Its Third Quarter 2026 Results on October 29 https://www.biopharmawatch.com/news/COR/cencora-fourth-quarter-fiscal-2026-earnings-release BiopharmaWatch en 2026-10-02T12:00:00.000Z Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release https://www.biopharmawatch.com/news/SRZN/surrozen-fda-clearance-ind-application-szn-8141 BiopharmaWatch en 2026-10-02T12:00:00.000Z Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema https://www.biopharmawatch.com/news/IART/integra-lifesciences-launches-600-million-term-loan BiopharmaWatch en 2026-10-02T12:00:00.000Z Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B https://www.biopharmawatch.com/news/CELC/celcuity-appoints-david-gryska-board-directors BiopharmaWatch en 2026-10-02T12:00:00.000Z Celcuity Appoints David Gryska To Its Board Of Directors https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-nasdaq-listing-rule-5635-20261002 BiopharmaWatch en 2026-10-02T12:00:00.000Z Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/HYPD/hyperion-defi-share-buybacks-debt-retirement BiopharmaWatch en 2026-10-02T12:00:00.000Z Hyperion DeFi Commences Share Buybacks, Retires All Legacy Debt, and Commits to Further Capital Optimization https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T11:59:00.000Z Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/VSTM/verastem-analyses-avutometinib-defactinib-igcs-2026 BiopharmaWatch en 2026-10-02T11:30:00.000Z Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-nasdaq-listing-rule-20261002 BiopharmaWatch en 2026-10-02T11:30:00.000Z Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KURA/kura-oncology-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261002 BiopharmaWatch en 2026-10-02T11:30:00.000Z Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/IFRX/inflarx-present-late-breaking-preclinical-data-izicopan-kidney-week-2026 BiopharmaWatch en 2026-10-02T11:30:00.000Z InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026 https://www.biopharmawatch.com/news/CYTK/cytokinetics-hfsa-annual-scientific-meeting-2026 BiopharmaWatch en 2026-10-02T11:30:00.000Z Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026 https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-closes-282-million-offering BiopharmaWatch en 2026-10-02T11:00:00.000Z Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering https://www.biopharmawatch.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-nasdaq-listing-rule BiopharmaWatch en 2026-10-02T11:00:00.000Z Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grants-20261002 BiopharmaWatch en 2026-10-02T11:00:00.000Z Cartesian Therapeutics Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/CMPS/compass-pathways-announces-new-employee-inducement-grants-nasdaq-listing-rule-20261002 BiopharmaWatch en 2026-10-02T10:30:00.000Z Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/HIT/health-in-tech-attend-craig-hallum-conference BiopharmaWatch en 2026-10-02T10:30:00.000Z Health In Tech to Attend the 17th Annual Craig-Hallum Alpha Select Conference https://www.biopharmawatch.com/news/ANGO/jacobi-hospital-alpha-pe-research-fund-award BiopharmaWatch en 2026-10-02T10:00:00.000Z AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence https://www.biopharmawatch.com/news/ENSG/ensign-group-expansion-florida BiopharmaWatch en 2026-10-02T10:00:00.000Z The Ensign Group Announces Expansion Into Florida https://www.biopharmawatch.com/news/ENSG/ensign-group-acquires-washington-facilities BiopharmaWatch en 2026-10-02T10:00:00.000Z The Ensign Group Adds Operations in Washington https://www.biopharmawatch.com/news/ENSG/ensign-group-expands-operations-colorado BiopharmaWatch en 2026-10-02T10:00:00.000Z The Ensign Group Adds New Operations in Colorado https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-clinical-trial-collaboration-ivonescimab BiopharmaWatch en 2026-10-02T06:30:00.000Z Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway https://www.biopharmawatch.com/news/AZN/daiichi-sankyo-astrazeneca-clinical-trial-collaboration BiopharmaWatch en 2026-10-02T06:30:00.000Z Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-executive-management-changes BiopharmaWatch en 2026-10-02T05:00:00.000Z Addex Therapeutics Announces Executive Management Changes https://www.biopharmawatch.com/news/NVS/abogen-novartis-licensing-agreement-mrna-therapeutics BiopharmaWatch en 2026-10-02T04:42:00.000Z Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs https://www.biopharmawatch.com/news/CGEM/zipalertinib-nda-submission-egfr-nsclc BiopharmaWatch en 2026-10-01T23:30:07.000Z New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program https://www.biopharmawatch.com/news/AXGN/axogen-acquires-biocircuit-nervetape-device BiopharmaWatch en 2026-10-01T21:19:00.000Z Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T21:10:00.000Z Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NUMIF/numinus-wellness-founders-resume-executive-roles BiopharmaWatch en 2026-10-01T21:00:00.000Z Numinus Wellness Founders to Resume Original Executive Roles https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T21:00:00.000Z Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/HYFT/mindwalk-nomme-kim-remizowski-au-conseil-d-apos-administration-titre BiopharmaWatch en 2026-10-01T20:50:00.000Z MindWalk nomme Kim Remizowski au conseil d'administration à titre d'administrateur indépendant https://www.biopharmawatch.com/news/ELUT/elutia-boston-scientific-payment-2026 BiopharmaWatch en 2026-10-01T20:45:00.000Z Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-underwritten-offering-2026 BiopharmaWatch en 2026-10-01T20:31:00.000Z Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T20:30:29.000Z X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/EHC/encompass-health-2026-q3-earnings-call BiopharmaWatch en 2026-10-01T20:30:00.000Z Encompass Health announces date of 2026 third-quarter earnings call https://www.biopharmawatch.com/news/EW/edwards-lifesciences-fda-approval-autus-valve BiopharmaWatch en 2026-10-01T20:26:00.000Z Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients https://www.biopharmawatch.com/news/ADRX/adarx-pharmaceuticals-ipo-shares-exercise BiopharmaWatch en 2026-10-01T20:15:00.000Z ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering https://www.biopharmawatch.com/news/NBTX/nanobiotix-appoints-arnd-christ-cfo BiopharmaWatch en 2026-10-01T20:15:00.000Z NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer https://www.biopharmawatch.com/news/STLN/starling-oncology-industry-conference-participation BiopharmaWatch en 2026-10-01T20:14:00.000Z Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation https://www.biopharmawatch.com/news/ABCL/abcellera-q3-2026-financial-results BiopharmaWatch en 2026-10-01T20:05:00.000Z AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-q3-2026-results-announcement BiopharmaWatch en 2026-10-01T20:05:00.000Z Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/CNMD/conmed-corporation-third-quarter-2026-results BiopharmaWatch en 2026-10-01T20:05:00.000Z CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026 https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T20:05:00.000Z Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MLYS/mineralys-lorundrostat-presentation-aha-2026 BiopharmaWatch en 2026-10-01T20:05:00.000Z Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026 https://www.biopharmawatch.com/news/RMD/resmed-report-first-quarter-fiscal-2027-earnings BiopharmaWatch en 2026-10-01T20:05:00.000Z Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026 https://www.biopharmawatch.com/news/SLDB/solid-biosciences-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T20:05:00.000Z Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KPTI/karyopharm-reports-inducement-grant-nasdaq-rule-5635 BiopharmaWatch en 2026-10-01T20:05:00.000Z Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261001 BiopharmaWatch en 2026-10-01T20:05:00.000Z Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-cpt-codes-approval BiopharmaWatch en 2026-10-01T20:03:00.000Z Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel https://www.biopharmawatch.com/news/REPL/tudriqev-available-us-advanced-melanoma BiopharmaWatch en 2026-10-01T20:01:00.000Z Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma https://www.biopharmawatch.com/news/ARVN/arvinas-phase-1-arv-102-parkinsons-congress-2026 BiopharmaWatch en 2026-10-01T20:01:00.000Z Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® https://www.biopharmawatch.com/news/MDT/medtronic-cpt-code-approvals-altaviva-symplicity-spyral BiopharmaWatch en 2026-10-01T20:00:00.000Z Medtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems https://www.biopharmawatch.com/news/MGRX/mangoceuticals-secures-strategic-investment-in-mangorx-ip BiopharmaWatch en 2026-10-01T19:50:00.000Z Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche https://www.biopharmawatch.com/news/MPH/medicure-grant-stock-options BiopharmaWatch en 2026-10-01T18:35:00.000Z Medicure Announces Grant of Stock Options https://www.biopharmawatch.com/news/SYK/stryker-syk-peripheral-vascular-issues-investigation BiopharmaWatch en 2026-10-01T18:21:00.000Z Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS https://www.biopharmawatch.com/news/TTAN/servicetitan-revenue-timing-issues-stock-drop BiopharmaWatch en 2026-10-01T18:19:00.000Z ServiceTitan (NASDAQ: TTAN) Scrutinized Over Surprise Revenue Timing and Other Issues Driving Stock Down 30% -- HBSS https://www.biopharmawatch.com/news/COSM/cosmos-health-global-market-expansion BiopharmaWatch en 2026-10-01T15:58:00.000Z Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-q3-2026-financial-results BiopharmaWatch en 2026-10-01T15:30:00.000Z IDEXX Laboratories to Release 2026 Third Quarter Financial Results https://www.biopharmawatch.com/news/ABBV/abbvie-rinvoq-repigmentation-non-segmental-vitiligo BiopharmaWatch en 2026-10-01T14:06:19.906Z AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo https://www.biopharmawatch.com/news/CDRE/lilysilk-renews-partnership-nbcf-a-bloom-of-care BiopharmaWatch en 2026-10-01T14:00:00.000Z Cinq ans de mode engagée : LILYSILK renouvelle son partenariat avec la National Breast Cancer Foundation dans le cadre de la campagne « A Bloom of Care » https://www.biopharmawatch.com/news/STVN/ensera-alliance-network-launch-partnerships BiopharmaWatch en 2026-10-01T13:32:00.000Z Ensera lance un réseau de partenariat avec SHL Medical, Stevanato Group, Ypsomed, Argonaut et American Injectables https://www.biopharmawatch.com/news/STVN/ensera-alliance-network-launch BiopharmaWatch en 2026-10-01T13:32:00.000Z Ensera startet Allianz-Netzwerk mit SHL Medical, der Stevanato Group, Ypsomed, Argonaut und American Injectables https://www.biopharmawatch.com/news/FFR/ffr-faraday-future-robotics-acquisition-update BiopharmaWatch en 2026-10-01T13:31:00.000Z FF EAI Robotics Ecosystem Inc. (Nasdaq: FFR) and Faraday Future Intelligent Electric Inc. (FFAI) Jointly Address Key Investor Questions Regarding the Proposed Acquisition of FFAI's Robotics Business https://www.biopharmawatch.com/news/GANX/gain-therapeutics-rexaceract-phase-1b-data BiopharmaWatch en 2026-10-01T13:28:00.000Z Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-dr-robert-spiegel-appointment BiopharmaWatch en 2026-10-01T13:20:00.000Z Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic https://www.biopharmawatch.com/news/PYPD/eu-ema-validates-polypids-marketing-authorization-application BiopharmaWatch en 2026-10-01T13:15:00.000Z European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀ https://www.biopharmawatch.com/news/BCDA/biocardia-revised-de-novo-pre-submission-fda-helix-catheter BiopharmaWatch en 2026-10-01T13:15:00.000Z BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-pancreatic-cancer-strategy BiopharmaWatch en 2026-10-01T13:02:00.000Z AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-submits-hcpcs-application-lytenava BiopharmaWatch en 2026-10-01T13:01:00.000Z Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg) https://www.biopharmawatch.com/news/NVCR/novocure-optune-pax-approval-japan-pancreatic-cancer BiopharmaWatch en 2026-10-01T13:00:00.000Z Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer https://www.biopharmawatch.com/news/WAT/waters-corporation-q3-2026-earnings-call BiopharmaWatch en 2026-10-01T13:00:00.000Z Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/LEGN/legend-biotech-launches-elite-grant-program BiopharmaWatch en 2026-10-01T13:00:00.000Z Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma https://www.biopharmawatch.com/news/CARL/carlsmed-appoints-tony-jarc-chief-product-ai-officer BiopharmaWatch en 2026-10-01T13:00:00.000Z Carlsmed Appoints Tony Jarc as Chief Product and AI Officer https://www.biopharmawatch.com/news/CHE/chemed-third-quarter-2026-earnings-report BiopharmaWatch en 2026-10-01T13:00:00.000Z Chemed To Report Third Quarter 2026 Earnings October 27, Related Conference Call To Be Held On October 28 https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-lx2006-presentation-mds-2026 BiopharmaWatch en 2026-10-01T13:00:00.000Z Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS) https://www.biopharmawatch.com/news/PYPD/polypid-regains-european-rights-d-plex1800 BiopharmaWatch en 2026-10-01T12:56:00.000Z PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities https://www.biopharmawatch.com/news/DGX/haystack-mrd-demonstrates-clinical-performance-dynamic-trials BiopharmaWatch en 2026-10-01T12:52:00.000Z Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials https://www.biopharmawatch.com/news/HYFT/mindwalk-appoints-kim-remizowski-independent-director BiopharmaWatch en 2026-10-01T12:46:00.000Z MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-announces-treatment-second-patient-fifth-cohort-ovarian-cancer BiopharmaWatch en 2026-10-01T12:35:00.000Z Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-age-better-campaign-kelly-slater BiopharmaWatch en 2026-10-01T12:32:00.000Z Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater https://www.biopharmawatch.com/news/SABS/sab-bio-present-sab-142-data-breakthrough-t1d-congress BiopharmaWatch en 2026-10-01T12:30:47.000Z SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress https://www.biopharmawatch.com/news/OSTX/os-therapies-appoints-kerry-clem-frank-knuettel BiopharmaWatch en 2026-10-01T12:30:00.000Z OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer https://www.biopharmawatch.com/news/ALGN/align-technology-third-quarter-2026-results BiopharmaWatch en 2026-10-01T12:30:00.000Z Align Technology to Announce Third Quarter 2026 Results on October 28, 2026 https://www.biopharmawatch.com/news/QTI/qt-imaging-cpt-code-3d-breast-imaging BiopharmaWatch en 2026-10-01T12:30:00.000Z QT Imaging Announces CPT® Category III Code for 3D Breast Acoustic Imaging Now Effective https://www.biopharmawatch.com/news/EOLS/evolus-launches-wings-charitable-platform BiopharmaWatch en 2026-10-01T12:30:00.000Z Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes https://www.biopharmawatch.com/news/ACOG/alpha-cognition-converge-real-world-evidence-zunveyl BiopharmaWatch en 2026-10-01T12:30:00.000Z Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care https://www.biopharmawatch.com/news/VIR/vir-biotechnology-appoints-aziz-sawaf-cfo BiopharmaWatch en 2026-10-01T12:30:00.000Z Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer https://www.biopharmawatch.com/news/MDAI/spectral-ai-deepview-system-clinical-study-burns BiopharmaWatch en 2026-10-01T12:30:00.000Z Spectral AI Announces First Site Initiation Visit for DeepView System™ Clinical Study Supporting Label Expansion Strategy to Burns of the Head, Hands, and Feet https://www.biopharmawatch.com/news/NXL/nexalin-technology-distribution-agreement-brazil-south-america BiopharmaWatch en 2026-10-01T12:30:00.000Z Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation https://www.biopharmawatch.com/news/ACHV/achieve-life-sciences-appoints-benjamin-halladay-cfo BiopharmaWatch en 2026-10-01T12:30:00.000Z Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer https://www.biopharmawatch.com/news/RNXT/renovorx-peer-reviewed-publication-tamp-platform BiopharmaWatch en 2026-10-01T12:30:00.000Z RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-pct-filing-adc-payload-cancer BiopharmaWatch en 2026-10-01T12:25:00.000Z Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-rezpegaldesleukin-eadv-2026 BiopharmaWatch en 2026-10-01T12:23:00.000Z /C O R R E C T I O N -- Nektar Therapeutics/ https://www.biopharmawatch.com/news/ICU/new-icd-10-pcs-codes-seastar-medical-scd-therapy BiopharmaWatch en 2026-10-01T12:21:00.000Z New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI) https://www.biopharmawatch.com/news/CADL/candel-therapeutics-phase-2a-trial-results-nsclc BiopharmaWatch en 2026-10-01T12:05:00.000Z Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI https://www.biopharmawatch.com/news/BTSG/brightspring-health-services-q3-2026-results BiopharmaWatch en 2026-10-01T12:05:00.000Z BrightSpring Health Services, Inc. to Announce Third Quarter 2026 Financial Results on October 30, 2026 https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-poster-presentation-european-narcolepsy-days BiopharmaWatch en 2026-10-01T12:05:00.000Z Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days https://www.biopharmawatch.com/news/MCK/mckesson-cvs-health-distribution-agreement-extension BiopharmaWatch en 2026-10-01T12:03:00.000Z McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-babesiosis-study-webinar BiopharmaWatch en 2026-10-01T12:03:00.000Z 60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar https://www.biopharmawatch.com/news/LABT/lakewood-amedev-biotherapeutics-october-conferences BiopharmaWatch en 2026-10-01T12:02:00.000Z Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences https://www.biopharmawatch.com/news/A/agilent-novostation-sample-preparation-system-launch BiopharmaWatch en 2026-10-01T12:00:00.000Z Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows https://www.biopharmawatch.com/news/EVMN/evommune-evo301-phase-2a-atopic-dermatitis-eadv-2026 BiopharmaWatch en 2026-10-01T12:00:00.000Z Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress https://www.biopharmawatch.com/news/OGN/organon-real-world-analysis-vtama-fall-conference BiopharmaWatch en 2026-10-01T12:00:00.000Z Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference https://www.biopharmawatch.com/news/BFLY/mendaera-focalist-butterfly-ultrasound-chip-technology BiopharmaWatch en 2026-10-01T12:00:00.000Z Mendaera’s Focalist™ System Now Compatible with Butterfly’s Ultrasound-on-Chip™ Technology https://www.biopharmawatch.com/news/MOH/molina-healthcare-nebraska-lead-testing-donation BiopharmaWatch en 2026-10-01T12:00:00.000Z Molina Healthcare of Nebraska Donates $30,000 to Support Lead Testing in Over 20 Rural Counties https://www.biopharmawatch.com/news/AZTR/azitra-advances-atr-04-phase-1-2-trial-cohort-2 BiopharmaWatch en 2026-10-01T12:00:00.000Z Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-muc16-ovarian-cancer-igcs-2026 BiopharmaWatch en 2026-10-01T12:00:00.000Z Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026 https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-reports-inducement-grants-permitted-nasdaq-listing-rules-20261001 BiopharmaWatch en 2026-10-01T12:00:00.000Z Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules https://www.biopharmawatch.com/news/ABBV/abbvie-third-quarter-2026-earnings-call BiopharmaWatch en 2026-10-01T12:00:00.000Z AbbVie to Host Third-Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/AKTS/aktis-oncology-phase-1b-trial-aky-2519 BiopharmaWatch en 2026-10-01T12:00:00.000Z Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3 https://www.biopharmawatch.com/news/DXR/daxor-showcase-next-gen-blood-volume-analyzer-hfsa-2026 BiopharmaWatch en 2026-10-01T12:00:00.000Z Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026 https://www.biopharmawatch.com/news/SYK/stryker-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-01T12:00:00.000Z Stryker to announce third quarter 2026 financial results https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-backbeat-trial-enrollment-exceeds-target BiopharmaWatch en 2026-10-01T12:00:00.000Z Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-tsha-102-rett-syndrome-presentations BiopharmaWatch en 2026-10-01T12:00:00.000Z Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting https://www.biopharmawatch.com/news/SGP/spyglass-pharma-acquires-advanced-vision-science BiopharmaWatch en 2026-10-01T12:00:00.000Z SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability https://www.biopharmawatch.com/news/MDLN/medline-lanza-la-campana-10-minutos-que-importan-para-destacar BiopharmaWatch en 2026-10-01T11:32:00.000Z Medline lanza la campaña «10 minutos que importan» para destacar el valor del tiempo en el quirófano https://www.biopharmawatch.com/news/NKTR/update-nektar-therapeutics BiopharmaWatch en 2026-10-01T11:30:00.000Z /UPDATE -- Nektar Therapeutics/ https://www.biopharmawatch.com/news/NKTR/rezpegaldesleukin-eadv-congress-2026 BiopharmaWatch en 2026-10-01T11:30:00.000Z New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 https://www.biopharmawatch.com/news/MDLN/10-minutes-that-make-difference-medline BiopharmaWatch en 2026-10-01T11:30:00.000Z Medline startet die Kampagne „10 Minuten, die den Unterschied machen ", um den Wert der Zeit im Operationssaal hervorzuheben https://www.biopharmawatch.com/news/IFRX/inflarx-appoints-gabriela-alperovich-as-svp-global-head-clinical-development BiopharmaWatch en 2026-10-01T11:30:00.000Z InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development https://www.biopharmawatch.com/news/ABUS/arbutus-final-results-230-million-tender-offer BiopharmaWatch en 2026-10-01T11:30:00.000Z Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer https://www.biopharmawatch.com/news/WVE/wave-life-sciences-fda-feedback-wve-006 BiopharmaWatch en 2026-10-01T11:30:00.000Z Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-allonk-sjogren-disease-issjd-2026 BiopharmaWatch en 2026-10-01T11:30:00.000Z Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026) https://www.biopharmawatch.com/news/HELP/helus-pharma-completes-legal-name-change BiopharmaWatch en 2026-10-01T11:30:00.000Z Helus Pharma Announces Completion of Legal Name Change https://www.biopharmawatch.com/news/MDLN/10-minutes-that-matter-medline-campaign BiopharmaWatch en 2026-10-01T11:29:00.000Z Medline lance la campagne « 10 Minutes That Matter » pour mettre en avant l'importance du temps au bloc opératoire https://www.biopharmawatch.com/news/MDLN/medline-10-minutes-that-matter-campaign BiopharmaWatch en 2026-10-01T11:27:00.000Z Medline launches "10 Minutes That Matter" campaign to spotlight the value of time in the operating theatre https://www.biopharmawatch.com/news/USNA/celebrate-international-music-day-usana BiopharmaWatch en 2026-10-01T11:07:00.000Z USANA CEO Kevin Guest Shares Three Ways to Celebrate International Music Day https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-meredith-manning-appointment BiopharmaWatch en 2026-10-01T11:05:00.000Z Unicycive Therapeutics Appoints Meredith Manning to Board of Directors https://www.biopharmawatch.com/news/HLF/herbalife-third-quarter-2026-results-announcement BiopharmaWatch en 2026-10-01T11:05:00.000Z Herbalife to Announce Third Quarter 2026 Results on November 2 https://www.biopharmawatch.com/news/KIDS/orthopediatrics-sponsors-pediatric-orthopedic-course BiopharmaWatch en 2026-10-01T11:05:00.000Z OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course https://www.biopharmawatch.com/news/SGHT/sight-sciences-launch-omni-ultra-surgical-system-aao-2026 BiopharmaWatch en 2026-10-01T11:05:00.000Z Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting https://www.biopharmawatch.com/news/EYE/rise-nano-optics-attend-cantech-conference-2026 BiopharmaWatch en 2026-10-01T11:00:00.000Z Rise Nano Optics to Attend the 2026 Cantech Investment Conference in Toronto https://www.biopharmawatch.com/news/MUSL/promino-tiktok-creator-content-triples BiopharmaWatch en 2026-10-01T11:00:00.000Z Promino TikTok Creator Content More Than Triples as Network Scales in First Full Quarter https://www.biopharmawatch.com/news/UNH/unitedhealthcare-2027-medicare-plans-affordability-simplicity BiopharmaWatch en 2026-10-01T11:00:00.000Z UnitedHealthcare 2027 Medicare Plans Focus on Affordability, Simplicity and a More Connected Healthcare Experience https://www.biopharmawatch.com/news/PODD/insulet-third-quarter-2026-financial-results-announcement BiopharmaWatch en 2026-10-01T11:00:00.000Z Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/NVCR/novocure-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-01T11:00:00.000Z Novocure to Report Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ELV/elevance-health-2027-medicare-advantage-plans BiopharmaWatch en 2026-10-01T11:00:00.000Z Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support https://www.biopharmawatch.com/news/DHR/julie-sawyer-montgomery-ceo-danaher BiopharmaWatch en 2026-10-01T11:00:00.000Z Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer https://www.biopharmawatch.com/news/STTK/shattuck-labs-phase-2-trial-sl-325-hidradenitis-suppurativa BiopharmaWatch en 2026-10-01T11:00:00.000Z Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-update-fhd-909-strategic-priorities BiopharmaWatch en 2026-10-01T11:00:00.000Z Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities https://www.biopharmawatch.com/news/GLUE/monte-rosa-positive-results-mrt-8102-gforce-1-study BiopharmaWatch en 2026-10-01T11:00:00.000Z Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-october-conferences-2026 BiopharmaWatch en 2026-10-01T11:00:00.000Z Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences https://www.biopharmawatch.com/news/BSEM/biostem-strengthens-patent-portfolio BiopharmaWatch en 2026-10-01T11:00:00.000Z BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio https://www.biopharmawatch.com/news/GENB/roswell-park-generate-biomedicines-gb-5267-trial BiopharmaWatch en 2026-10-01T11:00:00.000Z Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer https://www.biopharmawatch.com/news/KYNB/kyntra-bio-appoints-andrew-singer-board-directors BiopharmaWatch en 2026-10-01T11:00:00.000Z Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors https://www.biopharmawatch.com/news/IOVA/iova-appoints-noah-berkowitz-cmo BiopharmaWatch en 2026-10-01T11:00:00.000Z Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer https://www.biopharmawatch.com/news/FATE/fate-therapeutics-fourth-quarter-2026-conferences BiopharmaWatch en 2026-10-01T11:00:00.000Z Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-champions-in-care-movement BiopharmaWatch en 2026-10-01T10:59:00.000Z Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement https://www.biopharmawatch.com/news/CAH/cardinal-health-extends-distribution-agreement-cvs-health BiopharmaWatch en 2026-10-01T10:50:00.000Z Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health https://www.biopharmawatch.com/news/MRK/merck-third-quarter-2026-conference-call BiopharmaWatch en 2026-10-01T10:45:00.000Z Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 https://www.biopharmawatch.com/news/CAH/cardinal-health-first-quarter-results-fy-2027 BiopharmaWatch en 2026-10-01T10:45:00.000Z Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5 https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-easd-2026-clinical-data BiopharmaWatch en 2026-10-01T10:45:00.000Z Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting https://www.biopharmawatch.com/news/AGMB/agomab-positive-topline-data-ontunisertib-crohns-disease BiopharmaWatch en 2026-10-01T10:30:08.000Z Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease https://www.biopharmawatch.com/news/AVTR/avantor-third-quarter-2026-earnings-report BiopharmaWatch en 2026-10-01T10:05:00.000Z Avantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026 https://www.biopharmawatch.com/news/HIMS/hims-hers-appoints-chief-medical-officers-uk-australia BiopharmaWatch en 2026-10-01T10:00:00.000Z Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership https://www.biopharmawatch.com/news/KMTS/kestra-medical-five-star-rating-newsweek-2026 BiopharmaWatch en 2026-10-01T10:00:00.000Z Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies https://www.biopharmawatch.com/news/RDNT/radnet-win-nextgen-collaboration-medical-imaging BiopharmaWatch en 2026-10-01T10:00:00.000Z RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals https://www.biopharmawatch.com/news/TEVA/samsung-bioepis-teva-biosimilar-partnership-expansion BiopharmaWatch en 2026-10-01T08:30:00.000Z Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates https://www.biopharmawatch.com/news/STVN/ensera-launches-alliance-network-drug-device-combination-products BiopharmaWatch en 2026-10-01T08:00:00.000Z Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables https://www.biopharmawatch.com/blog/fda-calendar-q2-2026-key-pdufa-dates-upcoming-approvals BiopharmaWatch en 2026-10-01T07:16:38.266Z FDA Calendar: Upcoming PDUFA Dates and Drug Approval Decisions https://www.biopharmawatch.com/blog/Upcoming_Penny_Stock_Catalysts_in_June_2025_for_Biotech_and_Pharma_-_FDA_Calendar_and_PDUFA_Dates_to_Watch BiopharmaWatch en 2026-10-01T07:16:06.247Z Biotech Penny Stock Catalysts: FDA Calendar and PDUFA Dates for Small-Cap Pharma Stocks https://www.biopharmawatch.com/blog/fda-calendar-october-2026 BiopharmaWatch en 2026-10-01T07:15:30.907Z FDA Calendar October 2026: Key PDUFA Dates and Insights https://www.biopharmawatch.com/news/DTC/defence-therapeutics-world-adc-san-diego BiopharmaWatch en 2026-10-01T07:15:00.000Z Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates https://www.biopharmawatch.com/news/PFE/pfizer-tilrekimig-phase-2-atopic-dermatitis-study BiopharmaWatch en 2026-10-01T06:30:00.000Z Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study https://www.biopharmawatch.com/news/MEDS/datameds-ai-corexa-pharmacy-revenue-growth BiopharmaWatch en 2026-10-01T06:00:00.000Z DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue https://www.biopharmawatch.com/news/OCS/oculis-national-ms-society-campaign-end-ms BiopharmaWatch en 2026-10-01T06:00:00.000Z Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS https://www.biopharmawatch.com/news/SNY/sanofi-regeneron-expand-alliance-next-generation-antibodies BiopharmaWatch en 2026-10-01T05:00:00.000Z Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies https://www.biopharmawatch.com/news/SNY/regeneron-sanofi-global-alliance-next-gen-antibodies BiopharmaWatch en 2026-10-01T05:00:00.000Z Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies https://www.biopharmawatch.com/news/LLY/lilly-foundayo-reduces-diabetes-cardiovascular-risk BiopharmaWatch en 2026-10-01T00:00:00.000Z Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that... https://www.biopharmawatch.com/news/ACET/adicet-bio-reports-inducement-grant-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-09-30T23:12:00.000Z Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/UTHR/united-therapeutics-prevails-patent-litigation-liquidia BiopharmaWatch en 2026-09-30T23:09:00.000Z United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia